Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion
China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...
Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization
The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE)...
J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38...
New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits
China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its...
Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by...
AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga...
NHSA Releases Preliminary Review Results for National Reimbursement Drug List Adjustments
The National Healthcare Security Administration (NHSA) has released a notification disclosing the drugs that have...
Novartis Sets Tentative Date for Sandoz Spin-Off, Targets October 4
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced October 4 of this year as the...
Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first...
AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure
UK-based pharmaceutical major AstraZeneca plc (AZ, NASDAQ: AZN) has announced that China’s National Medical Products...
Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement
China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for...
MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study...
CARsgen Therapeutics Partners with Moderna to Combine CAR-T Therapy with mRNA Cancer Vaccine
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a collaboration agreement with US mRNA...
Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China
Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical...
Ezisurg Medical Partners partners with Vathin for Global Disposable Endoscope strategic partnership
Ezisurg Medical Co., Ltd has announced a strategic partnership with Hunan Vathin Medical Instrument Co.,...
Fosun Pharma Adjusts Investment Allocation for 2022 Non-Public Offering Projects
Fosun Pharma (SHA: 600196) has declared adjustments to the investment amounts for some of its...
HutchMed’s Sovleplenib Achieves Primary and Secondary Endpoints in ESLIM-01 Phase III Trial
China-based biopharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the pivotal...
Grand Pharmaceutical Group Initiates Phase I Study for Sepsis Treatment APAD
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the...
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Gastric Cancer
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its MET inhibitor, Orpathys (savolitinib),...